Chronic Myeloid Leukemia | Clinical

Ponatinib Demonstrates Efficacy Over Time for Patients With CP-CML After Prior TKI Failure

December 07, 2020

High response rates and robust survival outcomes among patients with chronic-phase chronic myeloid leukemia who failed prior treatment with a second-generation tyrosine kinase inhibitor were observed in 2 clinical trials of ponatinib,.

Clinical Trials Are Underway on Novel Approaches to CML-Resistant BCR-ABL1 Inhibitors

November 27, 2020

Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.

Emerging Therapies in CML Undergo Investigation in Chronic-Phase Illness

October 07, 2020

Today’s patients diagnosed with chronic myeloid leukemia can look forward to a near-normal life expectancy, provided they have good access to treatment and monitoring and are properly managed, said Jorge Cortes, MD.

Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic

June 24, 2020

During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.